AI
SUPN icon

Axiom Investors’s Supernus Pharmaceuticals SUPN Stock Holding History

Axiom Investors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39M Sell
94,465
-69,513
-42% -$3.34M 0.04% 114
2026
Q1 		$8.48M Buy
163,978
+57,793
+54% +$2.94M 0.09% 85
2025
Q4 		$5.28M Buy
106,185
+1,549
+1% +$75.3K 0.05% 103
2025
Q3 		$5M Buy
104,636
+48,521
+86% +$1.95M 0.04% 101
2025
Q2 		$1.77M Buy
56,115
+1,740
+3% +$55.8K 0.01% 124
2025
Q1 		$1.78M Sell
54,375
-15,521
-22% -$550K 0.02% 125
2024
Q4 		$2.53M Buy
69,896
+19,561
+39% +$689K 0.02% 120
2024
Q3 		$1.57M Sell
50,335
-4,525
-8% -$141K 0.01% 119
2024
Q2 		$1.47M Buy
54,860
+625
+1% +$18.1K 0.01% 122
2024
Q1 		$1.85M Buy
54,235
+5,780
+12% +$172K 0.02% 128
2023
Q4 		$1.4M Buy
48,455
+34,840
+256% +$924K 0.01% 129
2023
Q3 		$375K Sell
13,615
-10,285
-43% -$313K 0.01% 127
2023
Q2 		$718K Sell
23,900
-1,695
-7% -$59.3K 0.01% 121
2023
Q1 		$927K Buy
25,595
+5,355
+26% +$206K 0.02% 119
2022
Q4 		$722K Buy
+20,240
New +$703K 0.01% 120
2018
Q3 		– Sell
-57,230
Closed -$3.42M – 148
2018
Q2 		$3.42M Buy
57,230
+5,570
+11% +$289K 0.1% 103
2018
Q1 		$2.37M Sell
51,660
-5,030
-9% -$210K 0.06% 115
2017
Q4 		$2.26M Sell
56,690
-42,186
-43% -$1.67M 0.06% 114
2017
Q3 		$3.96M Sell
98,876
-72,955
-42% -$3.16M 0.09% 98
2017
Q2 		$7.41M Buy
171,831
+46,821
+37% +$1.67M 0.18% 72
2017
Q1 		$3.91M Buy
125,010
+25,146
+25% +$674K 0.1% 89
2016
Q4 		$2.52M Buy
+99,864
New +$2.23M 0.07% 113

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Axiom Investors's SUPN Position: Q2 2026 in Review

Axiom Investors reduced its Supernus Pharmaceuticals (SUPN) stake by 42% in Q2 2026, selling an estimated $3.34M and leaving 94,465 shares worth $4.39M. The position accounts for 0.04% of the portfolio, ranked #114.

Axiom Investors first reported a position in SUPN in Q4 2016 and has held it in 22 quarters since. The position peaked at $8.48M in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Axiom Investors held 94,465 shares of Supernus Pharmaceuticals worth $4.39M as of Q2 2026.
  • Axiom Investors sold 69,513 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.34M.
  • Supernus Pharmaceuticals made up 0.04% of Axiom Investors's portfolio in Q2 2026, its #114 holding.
  • Axiom Investors first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 22 quarters since.
  • Axiom Investors's Supernus Pharmaceuticals position peaked at $8.48M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Axiom Investors's 13F filing for Q2 2026, filed 12 Aug 2026.